4:33 PM ET
8-K
Investor Presentation
Verastem Investor Presentation
Verastem Oncology (VSTM) has published an updated corporate presentation for November 2026 detailing its pipeline of RAS/MAPK pathway-driven cancer therapies. The presentation highlights the commercialization strategy for AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer (LGSOC) and provides updates on its clinical trial programs, including RAMP 301 and collaborations with GenFleet Therapeutics.